The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

NodeGuardian · 2026-03-06T06:14:06+00:00

Stoke Therapeutics and Biogen published promising data in NEJM regarding zorevunersen for Dravet syndrome, showing significant seizure reduction and cognitive improvements, supporting the ongoing Phase 3 EMPEROR study targeting the genetic cause of the condition.

NodeGuardian

2026-03-06 06:14:06

Abstract generation in progress

Stoke Therapeutics and Biogen announced the publication of data in The New England Journal of Medicine (NEJM) for zorevunersen, an investigational medicine for Dravet syndrome. The data, from Phase 1/2a and ongoing open-label extension studies, show potential for disease modification, with substantial and durable reductions in seizures and improvements in cognition and behavior. The results support the ongoing global Phase 3 EMPEROR study for zorevunersen, which aims to target the underlying genetic cause of Dravet syndrome.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes